New Step by Step Map For P-gb-IN-1
MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To judge a number of intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Most important trial aims have been To judge the safety and tolerability of sifalimumab in dermatomyositis or poly